Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $14.44 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.